Showing results (1-10 of 44) with videos related to

Sort By:
Pageof 5
Statistics in Medicine|September 23, 2022
Blinded sample size re-estimation for comparing over-dispersed count data incorporating follow-up lengthsMasataka Igeta, Shigeyuki Matsui
Pharmaceutical Statistics|March 7, 2019
Statistical testing strategies for assessing treatment efficacy and marker accuracy in phase III trialsTakahiro Nonaka, Masataka Igeta, Shigeyuki Matsui
Biometrics|March 27, 2018
Power and sample size calculation incorporating misspecifications of the variance function in comparative clinical trials with over-dispersed count dataMasataka Igeta, Kunihiko Takahashi, Shigeyuki Matsui
Blood Pressure|July 27, 2013
Effect of azilsartan versus candesartan on nocturnal blood pressure variation in Japanese patients with essential hypertensionHiromi Rakugi, Kazuomi Kario, Kazuaki Enya, et al.
Pharmaceutical Statistics|January 7, 2022
Regulatory issues and the potential use of Bayesian approaches for early drug approval systems in JapanAkihiro Hirakawa, Hiroyuki Sato, Masataka Igeta, et al.
Journal of Robotic Surgery|October 30, 2021
Potential advantages of robotic total gastrectomy for gastric cancer: a retrospective comparative cohort studyTsutomu Kumamoto, Yoshinori Ishida, Masataka Igeta, et al.
Clinical Nutrition ESPEN|September 13, 2025
Phase angle as a predictor of complications in acute stroke: A cohort studyKeisuke Honma, Tomoyuki Ogino, Koichiro Sota, et al.
In Vivo (Athens, Greece)|October 29, 2022
Differentiation of Angiomyolipoma With Minimal Fat from Clear Cell Renal Cell Carcinoma Using Non-contrast Multiparametric Magnetic Resonance ImagingWataru Jomoto, Haruyuki Takaki, Shingo Yamamoto, et al.
Oncology|December 25, 2022
Clinical Efficacy and Safety of Nivolumab in Malignant Non-Pleural Mesothelioma: A Multicenter, Open-Label, Single-Arm, Japanese Phase II Trial (Viola) ProtocolKozo Kuribayashi, Masataka Igeta, Takashi Daimon, et al.
Breast Cancer (Tokyo, Japan)|February 20, 2025
Development and internal validation of a predictive model of overall and progression-free survival in eribulin-treated patients with breast cancer based on baseline peripheral blood parametersKeiko Natori, Masataka Igeta, Takashi Morimoto, et al.
Pageof 5